Quick Answer
Regenerative Medical Technology Group Inc. reported Diluted EPS of $0.44 per share (loss) for fiscal year 2024.
Regenerative Medical Technology Group Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2024 | -$0.44 | +44.3% |
| 2023 | -$0.79 | -75.6% |
| 2022 | -$0.45 | +59.8% |
| 2021 | -$1.12 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.35 | -400.0% | -250.0% |
| June 30, 2025 | -$0.10 | +41.2% | -66.7% |
| March 31, 2025 | -$0.06 | +62.5% | +14.3% |
| September 30, 2024 | -$0.07 | +85.1% | +58.8% |
| June 30, 2024 | -$0.17 | -6.3% | -6.3% |
| March 31, 2024 | -$0.16 | -23.1% | +66.0% |
| September 30, 2023 | -$0.47 | -327.3% | -193.7% |
| June 30, 2023 | -$0.16 | -33.3% | -23.1% |
- Regenerative Medical Technology Group Inc. showed an increase of +44.3% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2024 period, Regenerative Medical Technology Group Inc.’s diluted eps has grown by 60.7% (from $1.12 per share (loss) to $0.44 per share (loss)).
- The most recent figure is from Regenerative Medical Technology Group Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on April 15, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: